Red Queen Therapeutics, co-founded by Apple Tree Partners and Harvard Medical School, launched with $55M Series A funding and a BARDA contract for a pan-influenza therapeutic.

Red Queen Therapeutics, a clinical-stage biotech, launched with $55M Series A funding from Apple Tree Partners. The company focuses on developing novel antiviral treatments for the general population and immunocompromised patients, with a contract from BARDA for preclinical development of a pan-influenza therapeutic. Co-founded by Apple Tree and Harvard Medical School's Loren Walensky, Red Queen's stapled lipopeptide platform technology allows rapid design and development of new antiviral therapies targeting viral fusion inhibition.

August 06, 2024
4 Articles